Erlotinib response in a NSCLC patient with a novel compound G719D+L861R mutation in EGFR

Similar Items

• Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
  od: Watanabe, Satoshi, i dr.
  Izdano: (2014)
• EGFR Exon 19 Deletion Mutations and Systemic/CNS Miliary Metastasis: Clinical Correlations and Response to Therapy
  od: Poonia, Seerat, i dr.
  Izdano: (2014)
• Targeted Therapies in NSCLC: Emerging oncogene targets following the success of EGFR
  od: Berge, Eamon M, i dr.
  Izdano: (2013)
• Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations
  od: OHARA, GEN, i dr.
  Izdano: (2020)
• EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?
  od: Wang, Qiushi, i dr.
  Izdano: (2013)